Akebia Q3 2024 Earnings Report
Key Takeaways
Akebia Therapeutics reported total revenues of $37.4 million for the third quarter of 2024, compared to $42.0 million for the third quarter of 2023. The net loss for the quarter was $20.0 million, compared to a net loss of $14.5 million for the same period in the previous year. The company is preparing for the U.S. market availability of Vafseo expected in January 2025.
Vafseo on track for U.S. market availability expected in January 2025.
Over 300,000 patients, representing approximately 60% of dialysis patient lives in the U.S., now covered under dialysis provider contracts for Vafseo.
Vafseo granted TDAPA reimbursement and issued a Level II Healthcare Common Procedure Coding System code.
Akebia partnered with U.S. Renal Care (USRC) to initiate a collaborative trial evaluating mortality and hospitalization outcomes for dialysis patients taking Vafseo.
Akebia
Akebia
Forward Guidance
Akebia expects its existing cash resources and cash from operations will be sufficient to fund its current operating plan, including the U.S. Vafseo launch, for at least two years.
Positive Outlook
- Vafseo on track for U.S. market availability expected in January 2025.
- Over 300,000 patients, representing approximately 60% of dialysis patient lives in the U.S., now covered under dialysis provider contracts for Vafseo.
- Vafseo granted TDAPA reimbursement and issued a Level II Healthcare Common Procedure Coding System code.
- Akebia partnered with U.S. Renal Care (USRC) to initiate a collaborative trial evaluating mortality and hospitalization outcomes for dialysis patients taking Vafseo.
- Existing cash resources and cash from operations will be sufficient to fund its current operating plan, including the U.S. Vafseo launch, for at least two years.